Expanding IP offering to help companies worldwide more easily create, protect, monitor and enforce intellectual property
London, UK, Philadelphia, US, & Brussels, Belgium, December 2, 2019—Clarivate Analytics plc (NYSE:CCC;CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today announced it has acquired Darts-ip, a leading provider of case law data and analytics for intellectual property (IP) professionals. Recently awarded best legal tech company by Trends Legal Awards in Belgium, Darts-ip’s case law data and supporting analytics solutions will be offered alongside Clarivate’s trusted patent, trademark and domain data and solutions, across Derwent™, CompuMark™ and MarkMonitor™, to help companies make smarter, faster decisions.
According to the World Intellectual Property Organization (WIPO), IP filing activity continues to grow at a rapid pace, setting new records in 2018[1]. This means it’s more important than ever to provide IP professionals with reliable and insightful data and analysis that can inform strategic and operational decisions.
Companies around the world currently rely on data from Darts-ip to quickly find relevant cases to support better legal decisions, optimize strategy, increase efficiency, reduce costs and monitor relevant litigation as it unfolds around the world. Combining solutions from Clarivate and legal content from Darts-ip will give users even greater context, access and visibility into the status of trademarks, patents, domains, designs and copyrights.
“We continue to enhance our offerings and reinforce our position as a trusted global partner by delivering critical data and deep domain expertise to innovators everywhere. The acquisition of Darts-ip helps us deliver on that promise by giving customers access to a much wider range of IP solutions and analytics that help solve their most difficult challenges,” said Jeff Roy, President, IP Group, Clarivate Analytics. “This is the third recent IP acquisition by Clarivate, demonstrating our commitment to making significant investments in our data, analytics and platform.”
“We are the only legal technology provider that gathers IP case law data worldwide in a detailed and organized manner and as such, we will be well-positioned alongside the range of trusted, global IP solutions from Clarivate,” said Evrard van Zuylen, Managing Director, Darts-ip. “Traditionally, global case law data was not indexed for IP research and often not available digitally, making research difficult. Our AI-driven solutions and analytics enable IP professionals to make more informed decisions through contextual data, making them a great fit for Clarivate’s wide range of IP offerings. We are proud to become part of a global organization with a great heritage in patents, trademarks and domains.”
# # #
About Clarivate Analytics
Clarivate Analytics™ is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. We have built some of the most trusted brands across the innovation lifecycle, including Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. Today, Clarivate Analytics is on a bold entrepreneurial mission to help customers reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.
About Darts-ip
Darts-ip provides information and analytics that support IP prosecution and litigation activities worldwide. Through our platform, IP professionals gain unparalleled insights into IP rights, companies, jurisdictions, legal topics and market trends.
Darts-ip users can quickly search and track nearly 5 million cases covering trademarks, patents, copyrights, designs & models, domain names, and unfair competition. A dedicated team of local legal experts, in partnership with cutting-edge AI and machine learning tools, extract key data points from every case. From prosecutors to litigators, R&D to business intelligence experts, Darts-ip’s smart tools help win cases, build strategies and identify new opportunities. For more information visit www.darts-ip.com.
Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.
Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.
Media Contact
Tabita Seagrave, Head of Communications, Clarivate Analytics
media.enquiries@clarivate.com
[1] https://www.wipo.int/edocs/pubdocs/en/wipo_pub_941_2019.pdf
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.